RAM
BCTX

Redmond Asset Management’s Briacell Therapeutics BCTX Stock Holding History

Redmond Asset Management’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-769
Closed -$131K – 155
2024
Q2 		$131K Sell
769
-118
-13% -$33.4K 0.04% 153
2024
Q1 		$381K Sell
887
-3
-0.3% -$1.65K 0.12% 130
2023
Q4 		$781K Sell
890
-29
-3% -$20.8K 0.25% 110
2023
Q3 		$861K Buy
919
+1
+0.1% +$979 0.31% 104
2023
Q2 		$884K Hold
918
– – 0.29% 104
2023
Q1 		$1.03M Hold
918
– – 0.35% 96
2022
Q4 		$602K Hold
918
– – 0.22% 127
2022
Q3 		$774K Sell
918
-2
-0.2% -$2.01K 0.29% 113
2022
Q2 		$796K Hold
920
– – 0.29% 114
2022
Q1 		$1.4M Buy
920
+6
+0.7% +$7.1K 0.42% 83
2021
Q4 		$1.14M Buy
914
+3
+0.3% +$3.93K 0.32% 113
2021
Q3 		$1.11M Buy
911
+33
+4% +$30.3K 0.35% 95
2021
Q2 		$702K Hold
878
– – 0.21% 138
2021
Q1 		$508K Buy
+878
New +$478K 0.16% 154

Other funds holding BCTX

Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Redmond Asset Management's BCTX Position: Q3 2024 in Review

Redmond Asset Management sold out of Briacell Therapeutics (BCTX) in Q3 2024, closing a stake of 769 shares — an estimated $131K sold.

Redmond Asset Management first reported a position in BCTX in Q1 2021 and held it in 14 quarters. The position peaked at $1.4M in Q1 2022. 21 funds tracked by Wall St. Rank hold BCTX as of Q3 2024.

  • Redmond Asset Management reported no remaining Briacell Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Redmond Asset Management sold 769 Briacell Therapeutics shares in Q3 2024, an estimated $131K.
  • Redmond Asset Management first reported a position in Briacell Therapeutics in Q1 2021 and held it in 14 quarters.
  • Redmond Asset Management's Briacell Therapeutics position peaked at $1.4M in Q1 2022.
  • 21 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q3 2024.

Based on Redmond Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.